{"id":31264,"date":"2014-09-16T12:57:10","date_gmt":"2014-09-16T16:57:10","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=31264"},"modified":"2014-09-16T12:57:10","modified_gmt":"2014-09-16T16:57:10","slug":"investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264","title":{"rendered":"Investors Lured By Avanir Pharmaceuticals Inc (NASDAQ:AVNR), As Its AVP-923 Trial Turns Out Successful"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 The stock of <strong>Avanir Pharmaceuticals Inc (NASDAQ:AVNR) <\/strong>is on the soaring <a href=\"http:\/\/www.marketwatch.com\/story\/avanir-pharmaceuticals-announces-positive-phase-ii-trial-results-for-avp-923-in-treatment-of-agitation-in-patients-with-alzheimers-disease-2014-09-15\" target=\"_blank\">spree<\/a>. At the end of day\u2019s trade on September 15, AVNR gained a whopping 5.75, i.e. around 85.31% of its net per unit dollar value. The organization notched up positive Phase II results pertaining to its renowned drug \u2013 AVP- 923.<\/p>\n<p style=\"text-align: justify;\">This is a great feat attained by Avanir Pharmaceuticals Inc (NASDAQ:AVNR) since this drug intends to provide a tongue-in-check portrayal of the efficiency with which it helps reduce the level of aggression and agitation and ensure better safety measures for patients crippled by the fomenting Alzheimer\u2019s disease!<\/p>\n<p style=\"text-align: justify;\"><strong>The Disorder Of Disdain<\/strong><\/p>\n<p style=\"text-align: justify;\">The trial focused on how the placebo drug efficaciously worked upon individuals based on Neuropsychiatric Inventory or NPI. The trial ran quite well, within the apt time period and there were no hideous repercussions of the drug upon the subjects. It is often stated that Alzheimer\u2019s disease has no prudent practice in vogue that could come as a respite to quell the sufferings of over 6 million people solely in the US, facing the treacherous disorder \u2013 Alzheimer\u2019s disease. The disease rampantly develops at a rapid pace amongst the aged population. By FY 2016, the net number of people expected to suffer at the current rate is deemed to escalate to 16 million.<\/p>\n<p style=\"text-align: justify;\"><strong>Views And Reviews<\/strong><\/p>\n<p style=\"text-align: justify;\">At the given rate, the prominence of AVP-923 is invariably of utmost importance. If the drug succeeds in launching into the market right in time, the Avanir Pharmaceuticals Inc (NASDAQ:AVNR) shall be duly benefited as the sales of the drug is liable to propel significantly. At such a premise, the overall revenues garnered are ought to rise, given the swelling markets, which constitute individuals in need of the drug!<\/p>\n<p style=\"text-align: justify;\">Jeffrey Cummings \u2013 MD and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health \u2013the chairman of the committee associated with study steering, conjectured that the successful trial is indeed an exciting proposition and can quell the distresses of affected families, increasing the company\u2019s revenues in return.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 The stock of Avanir Pharmaceuticals Inc (NASDAQ:AVNR) is on the soaring spree. At the end of day\u2019s trade on September [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":31265,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[9199,2502,9200,2503],"stock_ticker":[],"class_list":["post-31264","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-avanir-pharmaceuticals-inc","tag-avanir-pharmaceuticals-inc-nasdaqavnr","tag-jeffrey-cummings","tag-nasdaqavnr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investors Lured By Avanir Pharmaceuticals Inc (NASDAQ:AVNR), As Its AVP-923 Trial Turns Out Successful - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investors Lured By Avanir Pharmaceuticals Inc (NASDAQ:AVNR), As Its AVP-923 Trial Turns Out Successful - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 The stock of Avanir Pharmaceuticals Inc (NASDAQ:AVNR) is on the soaring spree. At the end of day\u2019s trade on September [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-16T16:57:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/avan.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"84\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Investors Lured By Avanir Pharmaceuticals Inc (NASDAQ:AVNR), As Its AVP-923 Trial Turns Out Successful\",\"datePublished\":\"2014-09-16T16:57:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264\"},\"wordCount\":354,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/avan.jpg\",\"keywords\":[\"Avanir Pharmaceuticals Inc\",\"Avanir Pharmaceuticals Inc. (NASDAQ:AVNR)\",\"Jeffrey Cummings\",\"NASDAQ:AVNR\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264\",\"name\":\"Investors Lured By Avanir Pharmaceuticals Inc (NASDAQ:AVNR), As Its AVP-923 Trial Turns Out Successful - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/avan.jpg\",\"datePublished\":\"2014-09-16T16:57:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/avan.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/avan.jpg\",\"width\":300,\"height\":84},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors Lured By Avanir Pharmaceuticals Inc (NASDAQ:AVNR), As Its AVP-923 Trial Turns Out Successful\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investors Lured By Avanir Pharmaceuticals Inc (NASDAQ:AVNR), As Its AVP-923 Trial Turns Out Successful - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264","og_locale":"en_US","og_type":"article","og_title":"Investors Lured By Avanir Pharmaceuticals Inc (NASDAQ:AVNR), As Its AVP-923 Trial Turns Out Successful - Wall Street PR","og_description":"Boston, MA 09\/16\/2014 (wallstreetpr) \u2013 The stock of Avanir Pharmaceuticals Inc (NASDAQ:AVNR) is on the soaring spree. At the end of day\u2019s trade on September [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-16T16:57:10+00:00","og_image":[{"width":300,"height":84,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/avan.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Investors Lured By Avanir Pharmaceuticals Inc (NASDAQ:AVNR), As Its AVP-923 Trial Turns Out Successful","datePublished":"2014-09-16T16:57:10+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264"},"wordCount":354,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/avan.jpg","keywords":["Avanir Pharmaceuticals Inc","Avanir Pharmaceuticals Inc. (NASDAQ:AVNR)","Jeffrey Cummings","NASDAQ:AVNR"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264","url":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264","name":"Investors Lured By Avanir Pharmaceuticals Inc (NASDAQ:AVNR), As Its AVP-923 Trial Turns Out Successful - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/avan.jpg","datePublished":"2014-09-16T16:57:10+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/avan.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/avan.jpg","width":300,"height":84},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/investors-lured-by-avanir-pharmaceuticals-inc-nasdaqavnr-as-its-avp-923-trial-turns-out-successful-31264#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Investors Lured By Avanir Pharmaceuticals Inc (NASDAQ:AVNR), As Its AVP-923 Trial Turns Out Successful"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=31264"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31264\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/31265"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=31264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=31264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=31264"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=31264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}